A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

To join this study, you need to be at least 18 years old. Your body mass index (BMI), which is a measure of your weight compared to your height, needs to be 35 or higher. This study welcomes both men and women, including people of all gender identities.

If you have type 2 diabetes, your average blood sugar level (HbA1c) needs to be below 10%. If you don't have type 2 diabetes, your HbA1c should be below 6.5%. If during the initial health checks your HbA1c is 6.5% or higher and you didn't know you had diabetes, your doctor would need to confirm if you have type 2 diabetes before you could join.

There are also some reasons why you might not be able to join. For example, if your weight has changed by more than 5% in the last three months, or if you've taken certain types of weight-loss medicines (like some GLP-1 medicines or amylin-like medicines) within the last six months, you wouldn't be able to take part in this specific study.

If you decide to take part in this study, you would first go through a screening process to check if you meet all the requirements. If you do, you'd then be randomly assigned to receive either the new medicine CagriSema or the existing medicine Semaglutide. This 'random assignment' means it's decided by chance which treatment you get, ensuring fairness in the study.

You would regularly receive your study medication and attend scheduled visits for health checks. These check-ups would involve assessments like measuring your weight, blood tests, and discussions about how you're feeling and any side effects you might be experiencing. The study team will explain everything clearly, and you'll have opportunities to ask questions. The total time you'd be involved in the study is about 83 weeks, which is roughly a year and eight months, including regular follow-ups.